Phuong N. Huynh

Array ( [id] => 19170988 [patent_doc_number] => 20240156962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA [patent_app_type] => utility [patent_app_number] => 18/499720 [patent_app_country] => US [patent_app_date] => 2023-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593614 [patent_doc_number] => 12577316 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Methods of use of anti-CD37 antibodies, monoclonal anti-CD37 antibodies [patent_app_type] => utility [patent_app_number] => 17/975353 [patent_app_country] => US [patent_app_date] => 2023-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 63 [patent_no_of_words] => 35030 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 370 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217861 [patent_doc_number] => 20240182565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/495109 [patent_app_country] => US [patent_app_date] => 2023-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19158043 [patent_doc_number] => 20240150750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/494165 [patent_app_country] => US [patent_app_date] => 2023-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142214 [patent_doc_number] => 20240141042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => MULTISPECIFIC NKp46 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/490804 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248753 [patent_doc_number] => 20240199740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => T CELL RECRUITING POLYPEPTIDES CAPABLE OF BINDING CD123 AND TCR ALPHA/BETA [patent_app_type] => utility [patent_app_number] => 18/486205 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067246 [patent_doc_number] => 20240101672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ANTI-PTCRA ANTIBODY-DRUG CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/482448 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19002070 [patent_doc_number] => 20240066141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => LINKERS, CONJUGATES AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/463715 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217891 [patent_doc_number] => 20240182595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => HYPERGLYCOSYLATED BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/463047 [patent_app_country] => US [patent_app_date] => 2023-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246905 [patent_doc_number] => 20240197889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => PROCESS FOR THE PREPARATION OF PEGYLATED DRUG-LINKERS AND INTERMEDIATES THEREOF [patent_app_type] => utility [patent_app_number] => 18/462325 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380964 [patent_doc_number] => 20240270834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NOVEL ANTIBODY FORMAT [patent_app_type] => utility [patent_app_number] => 18/242154 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18242154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067229 [patent_doc_number] => 20240101655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Novel Angiopoietin 2, VEGF Dual Antagonists [patent_app_type] => utility [patent_app_number] => 18/460677 [patent_app_country] => US [patent_app_date] => 2023-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16708 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638099 [patent_doc_number] => 12168700 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => Therapeutic use of mitochondria and combined mitochondrial agents [patent_app_type] => utility [patent_app_number] => 18/459892 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 59 [patent_no_of_words] => 26301 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403687 [patent_doc_number] => 20240287198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => ANTI-CD40 ANTIBODIES FOR USE IN PREVENTION OF GRAFT REJECTION [patent_app_type] => utility [patent_app_number] => 18/459922 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861936 [patent_doc_number] => 20230416372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => IMMUNOSILENCING Fc VARIANTS [patent_app_type] => utility [patent_app_number] => 18/457687 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18457687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359362 [patent_doc_number] => 20240261396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY [patent_app_type] => utility [patent_app_number] => 18/458043 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18458043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987810 [patent_doc_number] => 20240059779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => MULTIVALENT BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/452699 [patent_app_country] => US [patent_app_date] => 2023-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 241 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379308 [patent_doc_number] => 20240269178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/451816 [patent_app_country] => US [patent_app_date] => 2023-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19404017 [patent_doc_number] => 20240287528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TRANSGLUTAMINASE-MEDIATED CONJUGATION [patent_app_type] => utility [patent_app_number] => 18/446406 [patent_app_country] => US [patent_app_date] => 2023-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18446406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414170 [patent_doc_number] => 12497440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => CS1 targeted chimeric antigen receptor-modified T cells [patent_app_type] => utility [patent_app_number] => 18/349678 [patent_app_country] => US [patent_app_date] => 2023-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 3395 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 430 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349678 [rel_patent_id] =>[rel_patent_doc_number] =>)